FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule
This article was originally published in The Tan Sheet
Executive Summary
FDA's final rule for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs requires warnings and revisions that go beyond changes the agency proposed in a 2006 tentative final rule
You may also be interested in...
McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol
McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.
FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action
FDA will continue to take actions against dietary supplement products prompted by a lower tolerance for adverse events than for other types of products, a policy reflected in its request for a recall the Hydroxycut weight-loss product line
Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009
Firms entering or expanding their presence in the OTC drug and nutritional product markets as part of pharmaceutical industry shuffling in 2009 attracted the attention of stakeholders already competing in those markets